Literature DB >> 6431021

Requirement for IFN gamma in potentiation of interferon's antiviral and anticellular activities: identity of mouse and human systems.

W R Fleischmann, L A Schwarz, C M Fleischmann.   

Abstract

Potentiation was originally demonstrated as a nonadditive, synergistic enhancement of interferon (IFN) activity in the mouse system for mixed preparations containing MuIFN-alpha/beta and MuIFN-gamma. Potentiation of the antiviral and anticellular activities has now been studied for mouse and human systems, and in both systems IFN-alpha and IFN-beta interacted synergistically with IFN-gamma, but not with each other. Further, the antiviral and anticellular activities of IFN-alpha and IFN-beta were potentiated equally by IFN-gamma. Potentiation was demonstrated for HuIFNs with specific activities of 10(7) U/mg of protein and higher. Naturally produced and recombinant HuIFN-alpha s had the same relative abilities to be potentiated by HuIFN-gamma. It was concluded that IFN-gamma with either IFN-alpha or IFN-beta was essential for potentiation, that potentiation of anticellular and antiviral actions occurred in similar manners, and that a close correlation existed between potentiation in mouse and human systems. These results suggest that potentiation was caused by the interaction of two dissimilar IFN types (immune versus virus-type) and that potentiation studies in the mouse may be directly relevant for humans.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6431021     DOI: 10.1089/jir.1984.4.265

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  7 in total

1.  Lysing of fresh human tumor by a cytotoxic factor derived from autologous large granular lymphocytes independently of other known cytokines.

Authors:  A Uchida; T Fujimoto; Y Mizutani
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 2.  Regulation of cell growth by interferon.

Authors:  M Shearer; J Taylor-Papadimitriou
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

3.  Recombinant HuIFN-gamma prevents herpes simplex keratitis in African green monkeys: demonstration of synergism with recombinant HuIFN-alpha 2.

Authors:  D Neumann-Haefelin; R Sundmacher; H Frey; W Merk
Journal:  Med Microbiol Immunol       Date:  1985       Impact factor: 3.402

4.  Sensitivity of Ph 1 + CFU-GM to human recombinant interferon alpha and gamma alone and in combination.

Authors:  G Visani; D Russo; D Damiani; S Rizzi; M R Motta; R M Lemoli; C Poluzzi; R Fanin; E Zuffa; P Tosi
Journal:  Blut       Date:  1988-07

5.  Monocyte and interferon based therapy for the treatment of ovarian cancer.

Authors:  Daniel S Green; Ana T Nunes; Christina M Annunziata; Kathryn C Zoon
Journal:  Cytokine Growth Factor Rev       Date:  2016-03-15       Impact factor: 7.638

Review 6.  Cytokine control of inflammation and repair in the pathology of multiple sclerosis.

Authors:  Jane M Rodgers; Stephen D Miller
Journal:  Yale J Biol Med       Date:  2012-12-13

Review 7.  Tumor necrosis factor and interferon: cytokines in harmony.

Authors:  Eric Bartee; Mohamed R Mohamed; Grant McFadden
Journal:  Curr Opin Microbiol       Date:  2008-07-01       Impact factor: 7.934

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.